Janssen Pharmaceutica NV
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Janssen Pharmaceutica NV
ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the absence of neurotoxicities in clinical trials. The product will come at a huge price differential compared to on-market therapies, offering new hope to several patients.
Deal Snapshot: Pipeline gets $50m up front and a $25m equity investment in exchange for global rights to an M1 receptor antagonist cleared to move into Phase II in relapsing/remitting MS.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
While artificial intelligence has proven its value in drug discovery, for most companies, the power of their AI systems is only as strong as the data those systems are trained on. However, stakeholders – from individual companies to consortiums and service vendors -- are finding creative approaches to overcome the so-called data problem and strengthen their AI models.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.